Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Gain in cellular organization of inflammatory breast cancer: A 3D in vitro model that mimics the in vivo metastasis

Authors: Jorge Morales, Mary L Alpaugh

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

The initial step of metastasis in carcinomas, often referred to as the epithelial-mesenchymal transition (EMT), occurs via the loss of adherens junctions (e.g. cadherins) by the tumor embolus. This leads to a subsequent loss of cell polarity and cellular differentiation and organization, enabling cells of the embolus to become motile and invasive. However highly malignant inflammatory breast cancer (IBC) over-expresses E-cadherin. The human xenograft model of IBC (MARY-X), like IBC, displays the signature phenotype of an exaggerated degree of lymphovascular invasion (LVI) in situ by tumor emboli. An intact E-cadherin/α, β-catenin axis mediates the tight, compact clump of cells found both in vitro and in vivo as spheroids and tumor emboli, respectively.

Methods

Using electron microscopy and focused ion beam milling to acquire in situ sections, we performed ultrastructural analysis of both an IBC and non-IBC, E-cadherin positive cell line to determine if retention of this adhesion molecule contributed to cellular organization.

Results

Here we report through ultrastructural analysis that IBC exhibits a high degree of cellular organization with polar elements such as apical/lateral positioning of E-cadherin, apical surface microvilli, and tortuous lumen-like (canalis) structures. In contrast, agarose-induced spheroids of MCF-7, a weakly invasive E-cadherin positive breast carcinoma cell line, do not exhibit ultrastructural polar features.

Conclusions

This study has determined that the highly metastatic IBC with an exaggerated malignant phenotype challenges conventional wisdom in that instead of displaying a loss of cellular organization, IBC acquires a highly structured architecture.
These findings suggest that the metastatic efficiency might be linked to the formation and maintenance of these architectural features. The comparative architectural features of both the spheroid and embolus of MARY-X provide an in vitro model with tractable in vivo applications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Giepmans BN, van Ijzendoorn SC: Epithelial cell-cell junctions and plasma membrane domains. Biochim Biophys Acta. 2008, 1788 (4): 820-31.CrossRefPubMed Giepmans BN, van Ijzendoorn SC: Epithelial cell-cell junctions and plasma membrane domains. Biochim Biophys Acta. 2008, 1788 (4): 820-31.CrossRefPubMed
2.
3.
go back to reference Nejsum LN, Nelson WJ: A molecular mechanism directly linking E-cadherin adhesion to initiation of epithelial cell surface polarity. J Cell Biol. 2007, 178 (2): 323-335. 10.1083/jcb.200705094.CrossRefPubMedPubMedCentral Nejsum LN, Nelson WJ: A molecular mechanism directly linking E-cadherin adhesion to initiation of epithelial cell surface polarity. J Cell Biol. 2007, 178 (2): 323-335. 10.1083/jcb.200705094.CrossRefPubMedPubMedCentral
4.
go back to reference Halbleib JM, Nelson WJ: Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006, 20 (23): 3199-3214. 10.1101/gad.1486806.CrossRefPubMed Halbleib JM, Nelson WJ: Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006, 20 (23): 3199-3214. 10.1101/gad.1486806.CrossRefPubMed
5.
go back to reference Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996, 382 (6592): 638-642. 10.1038/382638a0.CrossRefPubMed Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996, 382 (6592): 638-642. 10.1038/382638a0.CrossRefPubMed
6.
go back to reference Shin K, Fogg VC, Margolis B: Tight junctions and cell polarity. Annu Rev Cell Dev Biol. 2006, 22: 207-235. 10.1146/annurev.cellbio.22.010305.104219.CrossRefPubMed Shin K, Fogg VC, Margolis B: Tight junctions and cell polarity. Annu Rev Cell Dev Biol. 2006, 22: 207-235. 10.1146/annurev.cellbio.22.010305.104219.CrossRefPubMed
7.
go back to reference Garrod D, Chidgey M: Desmosome structure, composition and function. Biochim Biophys Acta. 2008, 1778 (3): 572-587. 10.1016/j.bbamem.2007.07.014.CrossRefPubMed Garrod D, Chidgey M: Desmosome structure, composition and function. Biochim Biophys Acta. 2008, 1778 (3): 572-587. 10.1016/j.bbamem.2007.07.014.CrossRefPubMed
8.
go back to reference Scothern A, Garrod D: Visualization of desmosomes in the electron microscope. Methods Cell Biol. 2008, 88: 347-366. full_text.CrossRefPubMed Scothern A, Garrod D: Visualization of desmosomes in the electron microscope. Methods Cell Biol. 2008, 88: 347-366. full_text.CrossRefPubMed
9.
go back to reference Woodhouse EC, Chuaqui RF, Liotta LA: General mechanisms of metastasis. Cancer. 1997, 80 (8 Suppl): 1529-1537. 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F.CrossRefPubMed Woodhouse EC, Chuaqui RF, Liotta LA: General mechanisms of metastasis. Cancer. 1997, 80 (8 Suppl): 1529-1537. 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F.CrossRefPubMed
10.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
11.
go back to reference Vincent-Salomon A, Thiery JP: Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 2003, 5 (2): 101-106. 10.1186/bcr578.CrossRefPubMedPubMedCentral Vincent-Salomon A, Thiery JP: Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 2003, 5 (2): 101-106. 10.1186/bcr578.CrossRefPubMedPubMedCentral
12.
go back to reference Wodarz A, Nathke I: Cell polarity in development and cancer. Nat Cell Biol. 2007, 9 (9): 1016-1024. 10.1038/ncb433.CrossRefPubMed Wodarz A, Nathke I: Cell polarity in development and cancer. Nat Cell Biol. 2007, 9 (9): 1016-1024. 10.1038/ncb433.CrossRefPubMed
13.
go back to reference Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2 (6): 442-454. 10.1038/nrc822.CrossRefPubMed Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2 (6): 442-454. 10.1038/nrc822.CrossRefPubMed
14.
go back to reference Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998, 392 (6672): 190-193. 10.1038/32433.CrossRefPubMed Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998, 392 (6672): 190-193. 10.1038/32433.CrossRefPubMed
16.
go back to reference Kleer CG, van Golen KL, Braun T, Merajver SD: Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol. 2001, 14 (5): 458-464. 10.1038/modpathol.3880334.CrossRefPubMed Kleer CG, van Golen KL, Braun T, Merajver SD: Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol. 2001, 14 (5): 458-464. 10.1038/modpathol.3880334.CrossRefPubMed
17.
go back to reference Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, et al: Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003, 88 (5): 718-725. 10.1038/sj.bjc.6600807.CrossRefPubMedPubMedCentral Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, et al: Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003, 88 (5): 718-725. 10.1038/sj.bjc.6600807.CrossRefPubMedPubMedCentral
18.
go back to reference Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, et al: Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007, 110 (7): 1436-1444. 10.1002/cncr.22927.CrossRefPubMed Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, et al: Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007, 110 (7): 1436-1444. 10.1002/cncr.22927.CrossRefPubMed
19.
go back to reference Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH: A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999, 59 (20): 5079-5084.PubMed Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH: A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999, 59 (20): 5079-5084.PubMed
20.
go back to reference Tomlinson JS, Alpaugh ML, Barsky SH: An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001, 61 (13): 5231-5241.PubMed Tomlinson JS, Alpaugh ML, Barsky SH: An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001, 61 (13): 5231-5241.PubMed
21.
go back to reference Alpaugh ML, Tomlinson JS, Ye Y, Barsky SH: Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol. 2002, 161 (2): 619-628.CrossRefPubMedPubMedCentral Alpaugh ML, Tomlinson JS, Ye Y, Barsky SH: Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol. 2002, 161 (2): 619-628.CrossRefPubMedPubMedCentral
22.
go back to reference Alpaugh ML, Barsky SH: Reversible model of spheroid formation allows for high efficiency of gene delivery ex vivo and accurate gene assessment in vivo. Hum Gene Ther. 2002, 13 (10): 1245-1258. 10.1089/104303402320139023.CrossRefPubMed Alpaugh ML, Barsky SH: Reversible model of spheroid formation allows for high efficiency of gene delivery ex vivo and accurate gene assessment in vivo. Hum Gene Ther. 2002, 13 (10): 1245-1258. 10.1089/104303402320139023.CrossRefPubMed
23.
go back to reference Oktem G, Bilir A, Selvi N, Yurtseven ME, Vatansever S, Ates U, Uysal A, Omay SB: Chemotherapy influences inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) activity on 3D breast cancer cell line. Oncol Res. 2006, 16 (4): 195-203.PubMed Oktem G, Bilir A, Selvi N, Yurtseven ME, Vatansever S, Ates U, Uysal A, Omay SB: Chemotherapy influences inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) activity on 3D breast cancer cell line. Oncol Res. 2006, 16 (4): 195-203.PubMed
24.
go back to reference Guirado D, Aranda M, Vilches M, Villalobos M, Lallena AM: Dose dependence of the growth rate of multicellular tumour spheroids after irradiation. Br J Radiol. 2003, 76 (902): 109-116. 10.1259/bjr/30772617.CrossRefPubMed Guirado D, Aranda M, Vilches M, Villalobos M, Lallena AM: Dose dependence of the growth rate of multicellular tumour spheroids after irradiation. Br J Radiol. 2003, 76 (902): 109-116. 10.1259/bjr/30772617.CrossRefPubMed
25.
go back to reference Ponce de Leon V, Barrera-Rodriguez R: Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids. Cancer Cell Int. 2005, 5 (1): 20-10.1186/1475-2867-5-20.CrossRefPubMed Ponce de Leon V, Barrera-Rodriguez R: Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids. Cancer Cell Int. 2005, 5 (1): 20-10.1186/1475-2867-5-20.CrossRefPubMed
26.
go back to reference Feder-Mengus C, Ghosh S, Reschner A, Martin I, Spagnoli GC: New dimensions in tumor immunology: what does 3D culture reveal?. Trends Mol Med. 2008, 14 (8): 333-340. 10.1016/j.molmed.2008.06.001.CrossRefPubMed Feder-Mengus C, Ghosh S, Reschner A, Martin I, Spagnoli GC: New dimensions in tumor immunology: what does 3D culture reveal?. Trends Mol Med. 2008, 14 (8): 333-340. 10.1016/j.molmed.2008.06.001.CrossRefPubMed
27.
go back to reference dit Faute MA, Laurent L, Ploton D, Poupon MF, Jardillier JC, Bobichon H: Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis. 2002, 19 (2): 161-168. 10.1023/A:1014594825502.CrossRefPubMed dit Faute MA, Laurent L, Ploton D, Poupon MF, Jardillier JC, Bobichon H: Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis. 2002, 19 (2): 161-168. 10.1023/A:1014594825502.CrossRefPubMed
28.
go back to reference Ferber EC, Kajita M, Wadlow A, Tobiansky L, Niessen C, Ariga H, Daniel J, Fujita Y: A role for the cleaved cytoplasmic domain of E-cadherin in the nucleus. J Biol Chem. 2008, 283 (19): 12691-12700. 10.1074/jbc.M708887200.CrossRefPubMedPubMedCentral Ferber EC, Kajita M, Wadlow A, Tobiansky L, Niessen C, Ariga H, Daniel J, Fujita Y: A role for the cleaved cytoplasmic domain of E-cadherin in the nucleus. J Biol Chem. 2008, 283 (19): 12691-12700. 10.1074/jbc.M708887200.CrossRefPubMedPubMedCentral
29.
go back to reference Debnath J, Brugge JS: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 2005, 5 (9): 675-688. 10.1038/nrc1695.CrossRefPubMed Debnath J, Brugge JS: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 2005, 5 (9): 675-688. 10.1038/nrc1695.CrossRefPubMed
30.
go back to reference Yamada KM, Cukierman E: Modeling tissue morphogenesis and cancer in 3D. Cell. 2007, 130 (4): 601-610. 10.1016/j.cell.2007.08.006.CrossRefPubMed Yamada KM, Cukierman E: Modeling tissue morphogenesis and cancer in 3D. Cell. 2007, 130 (4): 601-610. 10.1016/j.cell.2007.08.006.CrossRefPubMed
31.
go back to reference Schmeichel KL, Bissell MJ: Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci. 2003, 116 (Pt 12): 2377-2388. 10.1242/jcs.00503.CrossRefPubMedPubMedCentral Schmeichel KL, Bissell MJ: Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci. 2003, 116 (Pt 12): 2377-2388. 10.1242/jcs.00503.CrossRefPubMedPubMedCentral
32.
go back to reference Kumar HR, Zhong X, Hoelz DJ, Rescorla FJ, Hickey RJ, Malkas LH, Sandoval JA: Three-dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids. Pediatr Surg Int. 2008, 24 (11): 1229-1234. 10.1007/s00383-008-2245-2.CrossRefPubMedPubMedCentral Kumar HR, Zhong X, Hoelz DJ, Rescorla FJ, Hickey RJ, Malkas LH, Sandoval JA: Three-dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids. Pediatr Surg Int. 2008, 24 (11): 1229-1234. 10.1007/s00383-008-2245-2.CrossRefPubMedPubMedCentral
33.
go back to reference Griffith LG, Swartz MA: Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol. 2006, 7 (3): 211-224. 10.1038/nrm1858.CrossRefPubMed Griffith LG, Swartz MA: Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol. 2006, 7 (3): 211-224. 10.1038/nrm1858.CrossRefPubMed
Metadata
Title
Gain in cellular organization of inflammatory breast cancer: A 3D in vitro model that mimics the in vivo metastasis
Authors
Jorge Morales
Mary L Alpaugh
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-462

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine